Quick Answer
Vicarious Surgical Inc. reported Research And Development Expense of $33.60 million for the year ending 2025.
- Vicarious Surgical Inc. showed a decrease of -16.3% in Research And Development Expense from 2024 to 2025.
- This data is from Vicarious Surgical Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $2.50 million | Q1 2021: $3.61 million | Q2 2021: $4.01 million | Q3 2021: $5.19 million | Q1 2022: $9.85 million | Q2 2022: $10.06 million | Q3 2022: $12.12 million | Q1 2023: $13.36 million | Q2 2023: $12.71 million | Q3 2023: $13.04 million | Q1 2024: $9.97 million | Q2 2024: $10.92 million | Q3 2024: $10.80 million | Q1 2025: $9.42 million | Q2 2025: $9.05 million | Q3 2025: $7.99 million.
- Over the full 6 years of available data (2020 to 2025), Vicarious Surgical Inc.'s Research And Development Expense has grown by 243.0%.
- Historical annual values: Fiscal year 2025: $33.60 million | Fiscal year 2024: $40.16 million | Fiscal year 2023: $47.58 million | Fiscal year 2022: $43.90 million | Fiscal year 2021: $22.06 million | Fiscal year 2020: $9.80 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: